全文获取类型
收费全文 | 46452篇 |
免费 | 3591篇 |
国内免费 | 1573篇 |
专业分类
耳鼻咽喉 | 71篇 |
儿科学 | 1630篇 |
妇产科学 | 223篇 |
基础医学 | 3099篇 |
口腔科学 | 184篇 |
临床医学 | 4587篇 |
内科学 | 4985篇 |
皮肤病学 | 285篇 |
神经病学 | 616篇 |
特种医学 | 1264篇 |
外国民族医学 | 15篇 |
外科学 | 11223篇 |
综合类 | 6592篇 |
现状与发展 | 5篇 |
预防医学 | 2399篇 |
眼科学 | 290篇 |
药学 | 7943篇 |
20篇 | |
中国医学 | 2670篇 |
肿瘤学 | 3515篇 |
出版年
2024年 | 80篇 |
2023年 | 631篇 |
2022年 | 1102篇 |
2021年 | 1496篇 |
2020年 | 1511篇 |
2019年 | 1454篇 |
2018年 | 1418篇 |
2017年 | 1494篇 |
2016年 | 1719篇 |
2015年 | 1735篇 |
2014年 | 2802篇 |
2013年 | 4059篇 |
2012年 | 2429篇 |
2011年 | 2609篇 |
2010年 | 2173篇 |
2009年 | 2174篇 |
2008年 | 2173篇 |
2007年 | 2296篇 |
2006年 | 2094篇 |
2005年 | 1911篇 |
2004年 | 1712篇 |
2003年 | 1430篇 |
2002年 | 1259篇 |
2001年 | 1109篇 |
2000年 | 887篇 |
1999年 | 763篇 |
1998年 | 656篇 |
1997年 | 677篇 |
1996年 | 601篇 |
1995年 | 597篇 |
1994年 | 557篇 |
1993年 | 487篇 |
1992年 | 417篇 |
1991年 | 343篇 |
1990年 | 321篇 |
1989年 | 300篇 |
1988年 | 272篇 |
1987年 | 223篇 |
1986年 | 156篇 |
1985年 | 266篇 |
1984年 | 220篇 |
1983年 | 161篇 |
1982年 | 146篇 |
1981年 | 123篇 |
1980年 | 106篇 |
1979年 | 77篇 |
1978年 | 95篇 |
1977年 | 58篇 |
1976年 | 80篇 |
1975年 | 51篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《Clinical genitourinary cancer》2022,20(5):442-451
IntroductionSelective internal radiation therapy (SIRT) is a potential treatment of primary renal cell carcinoma (RCC) deemed unsuitable for conventional therapy. RESIRT is the first-in-human study to evaluate safety and feasibility of SIRT for primary RCC.Patients and MethodsPatients with RCC, unsuitable for, or who declined conventional therapy, were eligible. A single transfemoral micro-catheter administration of yttrium-90 (Y-90) resin microspheres (SIR-Spheres) was delivered super selectively via the renal artery to the tumour at intended radiation doses of 75, 100, 150, 200, 300 Gy and a final cohort with a procedural endpoint of “imminent stasis,” in a dose-escalation design. Post-SIRT follow-up was 12 months. Study endpoints included safety and toxicity 30-days and 12-months post-SIRT and tumour response (RECIST v1.1).ResultsIn total, 21 patients were enrolled, mean (SD) age was 75 (9.3) years, WHO performance status was 0 in 81%, 12 (57%) had stage 3 chronic kidney disease, and 7 (33%) had prior contralateral nephrectomy. Overall, 71% of patients completed 12 months of follow-up. Intended doses were delivered without any dose-limiting toxicity. Seventeen out of 21 (81%) patients experienced an adverse event (AE) from any cause within 30 days post-SIRT; all SIRT-related AEs were grade 1 to 2. Best overall tumour responses were partial response 1/21 (4.8%), stable disease 19/21 (90.5%) and progressive disease 1/21 (4.8%).ConclusionThis study demonstrated good tolerability of SIRT at all dose levels including “imminent stasis” in treating primary tumours in RCC patients otherwise unsuitable for conventional therapy. SIRT with Y-90 resin microspheres may be a feasible treatment option for RCC. 相似文献
3.
4.
5.
Ariel Paracampo Marina Solis Carlos Bonetto 《International journal of environmental health research》2015,25(1):96-103
Chlorpyrifos is the most used insecticide in Argentina. Cnesterodon decemmaculatus is a widely distributed, endemic fish from Neotropical America. It attains high densities in the shallow water assemblages of Argentina and Brazil. The aim of this study was to assess the acute toxicity of chlorpyrifos to C. decemmaculatus. The mean 96-h LC50 of three independent determinations was 105.3 (±?3.1) μg/L. Sublethal effects were observed. Swimming behavioral changes at each chlorpyrifos exposure concentration were reported. C. decemmaculatus represents a good model for ecotoxicological risk assessment. 相似文献
6.
目的:应用99mTc-DTPA肾动脉显像评价Stanford不同分型主动脉夹层患者术后左、右侧肾功能及总体肾功能受损程度,帮助临床制定进一步的治疗方案,改善患者预后。方法:回顾性分析2018年3月8日至2019年7月19日,在本院核医学科行99mTc-DTPA肾动态显像的主动脉夹层术后患者48例,评价患者双肾血流灌注、总肾小球滤过率(GFR)和分肾的GFR,比较Stanford主动脉夹层A型(简称A型)患者和主动脉夹层B型(简称B型)患者之间总肾功能及分肾功能,血肌酐、血尿素氮及血尿酸水平的差异。结果:B型患者术后总GFR低于A型患者(67.5 vs.80.6 m L/min,P<0.05),其中以左肾功能受损为著(30.9 vs.40.3 m L/min,P<0.05),差异有统计学意义。结论:肾动态显像对主动脉夹层术后患者早期评价肾功能有重要价值。主动脉夹层B型患者GFR较A型减低,且左侧肾GFR减低更明显,临床可以早期采取干预措施,改善主动脉夹层患者预后。 相似文献
7.
Qianlai Luo Jonathan N. Hofmann Ruth M. Pfeiffer Cari M. Kitahara Minkyo Song Meredith S. Shiels 《International journal of cancer. Journal international du cancer》2023,153(1):64-72
In the United States, renal cell carcinoma (RCC) incidence and the prevalence of obesity, an established risk factor for RCC, have been increasing for several decades. RCC is more common among older individuals. We sought to quantify the contribution of excess adiposity to the rising incidence of RCC among individuals 60 years or older. National Institutes of Health-American Association of Retired Persons Diet and Health Study data (n = 453 859 participants, enrolled in 1995-1996, age at enrollment 50-71 years) were used to estimate multivariable-adjusted hazard ratios (HRs) for RCC across body mass index categories and HRs associated with smoking. Population attributable fractions (PAFs) were calculated using estimated HRs and annual overweight/obesity prevalence from the National Health Interview Survey (1985-2008). PAF estimates were combined with RCC incidence from Surveillance, Epidemiology and End Results-13 to calculate annual percent changes in RCC incidence attributable (and unrelated) to overweight/obesity. We found that between 1995 and 2018, among individuals aged 60 years and older, PAF for overweight/obesity increased from 18% to 29% for all RCCs. In comparison, the PAF for smoking declined from 12% to 9%. RCC incidence increased 1.8% per year (95% confidence interval [CI] 1.5%-2.1%) overall, while RCC incidence attributable to overweight/obesity increased 3.8% per year (95%CI 3.5%-4.2%) and RCC incidence unrelated to overweight/obesity increased 1.2% per year (95% CI 0.9%-1.4%). In conclusion, overweight/obesity appears to have contributed importantly to the rising incidence of RCC in the United States since the mid-1990s. Public health interventions focused on reducing overweight and obesity could help substantially in curbing this trend. 相似文献
8.
9.
Rapid industrial and technological development has impacted ecosystem homeostasis strongly. Arsenic is one of the most detrimental environmental toxins and its management with chelating agents remains a matter of concern due to associated adverse effects. Thus, safer and more effective alternative therapy is required to manage arsenic toxicity. Based on existing evidence, native and indigenous plant-based active biomolecules appear as a promising strategy to mitigate arsenic-induced toxicity with an acceptable safety profile. In this regard, various phytochemicals (flavonoids and stilbenoids) are considered important classes of polyphenolic compounds with antioxidant and chelation effects, which may facilitate the removal of arsenic from the body more effectively and safely with regard to conventional approaches. This review presents an overview of conventional chelating agents and the potential role of flavonoids and stilbenoids in ameliorating arsenic toxicity. This report may provide a roadmap for identifying novel prophylactic/therapeutic strategies for managing arsenic toxicity. 相似文献
10.